Buparlisib
Adult Solid Neoplasm
Roswell Park Cancer InstituteSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Adult Solid Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Roswell Park Cancer Institute | Phase 1/2 | BB |
Veliparib National Cancer Institute (NCI) | Phase 1/2 | BB |
Vinorelbine National Cancer Institute (NCI) | Phase 1/2 | BB |
azd6244 National Cancer Institute (NCI) | Phase 2 | BB |
Cediranib National Cancer Institute (NCI) | Phase 1/2 | B |
View all 50 →
Same molecule, other indications
Buparlisib is also rated in:
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaDormant
CCC
Indicative ·
54 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →